Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00101283 · OUTCOME

Overall Survival

Pemetrexed Plus Gemcitabine or Carboplatin for Patients With Advanced Malignant Pleural Mesothelioma · Source last updated 2023-07-03

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
Months
Interval / dispersion
95% Confidence Interval
Time frame
Assessed every 3 months for 2 years, then every 6 months for 1 year

What was measured

Time from randomization to death. Patients alive at last follow-up were censored.

Analysis population: The population consisted of all eligible, treated patients. 3 patients randomized to pemetrexed/gemcitabine who withdrew prior to treatment are excluded.

Groups in this outcome

Pemetrexed/Carboplatin

Pemetrexed disodium 500 mg/m2 IV over 10 minutes and carboplatin to AUC 5 IV over 30 minutes on day 1 of a 21-day cycle.

Pemetrexed/Gemcitabine

Pemetrexed disodium 500 mg/m2 IV over 10 minutes on day 1 and gemcitabine 1000 mg/m2 IV over 30 minutes on days 1 and 8 of a 21-day cycle.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Pemetrexed/Carboplatin16
Pemetrexed/Gemcitabine13

Reported measurements

Source class 1
Values in Months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Pemetrexed/Carboplatin13.0Not reported5.621.9Not reported
Pemetrexed/Gemcitabine6.0Not reported3.914.0Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        5.6
        upper Limit
        21.9
        value
        13.0
      2. group Id
        OG001
        lower Limit
        3.9
        upper Limit
        14.0
        value
        6.0
denoms
  1. counts
    1. group Id
      OG000
      value
      16
    2. group Id
      OG001
      value
      13
    units
    Participants
description
Time from randomization to death. Patients alive at last follow-up were censored.
dispersion Type
95% Confidence Interval
groups
  1. description
    Pemetrexed disodium 500 mg/m2 IV over 10 minutes and carboplatin to AUC 5 IV over 30 minutes on day 1 of a 21-day cycle.
    id
    OG000
    title
    Pemetrexed/Carboplatin
  2. description
    Pemetrexed disodium 500 mg/m2 IV over 10 minutes on day 1 and gemcitabine 1000 mg/m2 IV over 30 minutes on days 1 and 8 of a 21-day cycle.
    id
    OG001
    title
    Pemetrexed/Gemcitabine
param Type
MEDIAN
population Description
The population consisted of all eligible, treated patients. 3 patients randomized to pemetrexed/gemcitabine who withdrew prior to treatment are excluded.
reporting Status
POSTED
time Frame
Assessed every 3 months for 2 years, then every 6 months for 1 year
title
Overall Survival
type
SECONDARY
unit Of Measure
Months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice